Literature DB >> 21529288

Generation and characterization of rat anti-mouse ST2L monoclonal antibodies.

Natalie Fursov1, Erin Johnston, Karen Duffy, Adam Cotty, Theodore Petley, Jamie Fisher, Haiyan Jiang, Michael A Rycyzyn, Jill Giles-Komar, Gordon Powers.   

Abstract

ST2L is a transmembrane receptor that belongs to the IL-1 receptor family. The receptor is expressed on various cell types including Th2 cells, mast cells, basophils, growth-activated fibroblasts, and vascular endothelial cells. ST2L activation by its ligand IL-33 has been implicated in Th2-mediated immunity, inflammation, and allergic responses in vivo. Inhibition of ST2L activity can attenuate Th2-dominated immune responses such as lung eosinophilia, airway hyper-responsiveness, and arthritis in animal models. Here we report the generation and in vitro characterization of a panel of rat anti-mouse ST2L monoclonal antibodies. We demonstrate that the antibodies specifically bind to recombinant receptor protein and that a subset of the binders inhibits mouse ST2L activity in multiple in vitro assays. Four of the identified anti-mouse ST2L antibodies were shown to prevent IL-33 from binding to ST2L, down-regulate IL-33-induced NF-κB signaling, and neutralize the ability of IL-33 to stimulate mouse Th2 cell proliferation. The characterized monoclonal antibodies are important tools that will be used to study mouse ST2L receptor functionality in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529288     DOI: 10.1089/hyb.2010.0100

Source DB:  PubMed          Journal:  Hybridoma (Larchmt)        ISSN: 1554-0014


  5 in total

1.  IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury.

Authors:  Marta E Stremska; Sheethal Jose; Vikram Sabapathy; Liping Huang; Amandeep Bajwa; Gilbert R Kinsey; Poonam R Sharma; Saleh Mohammad; Diane L Rosin; Mark D Okusa; Rahul Sharma
Journal:  J Am Soc Nephrol       Date:  2017-05-24       Impact factor: 10.121

2.  Prospects to translate the biology of IL-33 and ST2 during organ transplantation into therapeutics to treat graft-versus-host disease.

Authors:  Ian C Scott; Kirsty F Houslay; E Suzanne Cohen
Journal:  Ann Transl Med       Date:  2016-12

3.  Targeting ST2L potentiates CpG-mediated therapeutic effects in a chronic fungal asthma model.

Authors:  Hemanth Ramaprakash; Takehiko Shibata; Karen E Duffy; Ugur B Ismailoglu; Rachel M Bredernitz; Ana Paula Moreira; Ana L Coelho; Anuk M Das; Natalie Fursov; Geoffrey L Chupp; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2011-05-14       Impact factor: 4.307

4.  ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease.

Authors:  Jilu Zhang; Abdulraouf M Ramadan; Brad Griesenauer; Wei Li; Matthew J Turner; Chen Liu; Reuben Kapur; Helmut Hanenberg; Bruce R Blazar; Isao Tawara; Sophie Paczesny
Journal:  Sci Transl Med       Date:  2015-10-07       Impact factor: 17.956

Review 5.  Galectin-3 and sST2 as Prognosticators for Heart Failure Requiring Extracorporeal Life Support: Jack n' Jill.

Authors:  Jianli Bi; Vidu Garg; Andrew R Yates
Journal:  Biomolecules       Date:  2021-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.